CD8⁺ T cells and NK cells are both cytotoxic effector cells of the immune system, but the recognition, specificity, sensitivity, and memory mechanisms are drastically different. While many of these topics have been extensively studied in CD8⁺ T cells, very little is known about NK cells. Current cancer immunotherapies mainly focus on CD8⁺ T cells, but have many issues of toxicity and efficacy. Given the heterogeneous nature of cancer, personalized cancer immunotherapy that integrates the power of both CD8⁺ T cells in adaptive immunity and NK cells in innate immunity might be the future direction, along with precision targeting and effective delivery of tumor-specific, memory CD8⁺ T cells and NK cells.

CD8 ⁺ T细胞和NK细胞都是免疫系统的细胞毒性效应细胞，但识别、特异性、敏感性和记忆机制却截然不同。虽然其中许多主题已在 CD8 ⁺ T 细胞中进行了广泛研究，但人们对 NK 细胞知之甚少。目前的癌症免疫疗法主要集中在CD8 ⁺ T细胞上，但存在许多毒性和疗效问题。鉴于癌症的异质性，整合适应性免疫中 CD8 ⁺ T 细胞和先天免疫中 NK 细胞的力量的个性化癌症免疫治疗可能是未来的方向，同时精准靶向和有效递送肿瘤特异性记忆 CD8 ⁺ T 细胞和 NK 细胞。